StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Aeterna Zentaris from $2.00 to $1.50 and set a “buy” rating for the company in a research note on Wednesday, March 30th.

Aeterna Zentaris stock opened at $0.32 on Tuesday. The firm’s 50 day simple moving average is $0.36 and its 200 day simple moving average is $0.43. The firm has a market capitalization of $38.47 million, a PE ratio of -4.53 and a beta of 1.61. Aeterna Zentaris has a 1-year low of $0.29 and a 1-year high of $1.17.

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) last released its quarterly earnings results on Tuesday, March 29th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.02). Aeterna Zentaris had a negative net margin of 294.42% and a negative return on equity of 13.55%. As a group, research analysts anticipate that Aeterna Zentaris will post -0.11 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC boosted its stake in shares of Aeterna Zentaris by 37.0% in the 4th quarter. Virtu Financial LLC now owns 134,129 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 36,221 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Aeterna Zentaris by 72.3% in the 3rd quarter. Geode Capital Management LLC now owns 91,492 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 38,395 shares in the last quarter. Natixis boosted its stake in shares of Aeterna Zentaris by 31.7% in the 3rd quarter. Natixis now owns 293,800 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 70,700 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Aeterna Zentaris by 207.6% in the 3rd quarter. Renaissance Technologies LLC now owns 341,400 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 230,400 shares in the last quarter. 1.56% of the stock is owned by institutional investors and hedge funds.

Aeterna Zentaris Company Profile (Get Rating)

Æterna Zentaris, Inc operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Further Reading